Press Releases

Date	Title	PDF Version
Dec 10, 2012	New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated with Soliris® Reported at ASH Annual Meeting
Nov 21, 2012	Alexion to Present at the 24th Annual Piper Jaffray Healthcare Conference
Nov 08, 2012	Alexion Announces $400 Million Share Repurchase Program
Nov 07, 2012	Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting
Nov 03, 2012	Two-Year Data Show Long-Term Benefits of Chronic Soliris® Therapy in Patients with aHUS
Nov 03, 2012	New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS
Oct 24, 2012	Alexion Reports Third Quarter 2012 Results
Oct 17, 2012	Alexion Pharmaceuticals to Report Third Quarter 2012 Results on Wednesday, October 24, 2012
Oct 10, 2012	Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS and STEC-HUS at ASN Annual Meeting
Oct 09, 2012	Data from Investigator-Initiated Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe Relapsing Neuromyelitis Optica (NMO) Presented at the American Neurological Association (ANA) Annual Meeting

Search